No Serious CV Risks for Elderly After Pfizer COVID-19 Vaccine
3 min read
fairly difficult
A French study adds to other evidence that the Pfizer mRNA COVID-19 vaccine does not increase the risk for serious cardiovascular adverse events in elderly individuals.
Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center.

A French population-based study provides further evidence that the BNT162b2 Pfizer-BioNTech mRNA COVID-19 vaccine does not increase the short-term risk for serious cardiovascular adverse events in older people.

The study showed no increased risk of myocardial infarction (MI), stroke, or pulmonary embolism (PE) following vaccination in adults aged 75 years or older in the 14 days following vaccination.

"These findings regarding the BNT162b2 vaccine's short-term cardiovascular safety profile in older people are reassuring. They should be taken into account by doctors when considering implementing a third dose of the vaccine in older people," Marie Joelle Jabagi, PharmD, PhD, with the French National Agency for Medicines and Health Products Safety, Saint-Denis, France, told | Medscape Cardiology.

The study was published as a research letter online November 22 in JAMA.

The Pfizer-BioNTech mRNA vaccine was the first SARS-CoV-2 vaccine authorized in France and has been widely used in older people. The phase 3 trials of the vaccine showed no increase in cardiovascular events, but older people were underrepresented in the trials.

As of April 30, 2021, nearly 3.9 million French adults aged 75 or…
Megan Brooks
Read full article